ClinicalTrials.gg

Program

pacibekitug

A development code. Also written as “Pacibekitug”.

Its studies are mostly in Myocardial Infarction, led by Novartis.

Furthest: phase 3, since Nov 9, 20261 company-led study, 1 open or runningNext primary completion: Oct 22, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 3since Nov 9, 2026Nov 9, 2026Oct 22, 2030phase 3 · NCT07938411
  • Named in Novartis’s own pipeline as PAC001 (pacibekitug), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2026First study: phase 3 study in Myocardial InfarctionFirst studyNCT07938411 · 10,000 planned

Ahead

  1. Oct 22, 2030Primary completion: phase 3 study in Myocardial InfarctionNCT07938411

TargetBeta

IL6 →read by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
ziltivekimabruleNovo Nordiskphase 312
clazakizumabCSLphase 310
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07938411Myocardial Infarction3Not yet recruitingOct 22, 203010,000

How it is read

Names in the registry

  • “Pacibekitug”, 1 entry

Codes read as this program: PAC001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 16, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.